Skip Navigation


JAC Advance Access originally published online on April 10, 2008
Journal of Antimicrobial Chemotherapy 2008 62(1):153-155; doi:10.1093/jac/dkn160
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/1/153    most recent
dkn160v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cateau, E.
Right arrow Articles by Imbert, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cateau, E.
Right arrow Articles by Imbert, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth

Estelle Cateau*, Marie-Hélène Rodier and Christine Imbert

Université de Poitiers, UMR CNRS 6008, Equipe de Microbiologie Fondamentale et Appliquée, 6 Rue de la Milètrie, BP 199, 86034 Poitiers Cedex, France

Received 10 December 2007; returned 21 January 2008; revised 7 March 2008; accepted 17 March 2008


* Corresponding author. Tel: +33-5-49-44-37-47; Fax: +33-5-49-44-39-08; E-mail: estelle.cateau{at}chu-poitiers.fr

Objectives: Caspofungin and micafungin belong to the echinocandins; the mechanism of action of echinocandins is based on the inhibition of (1,3)-β-D-glucan synthase. The aim of this study was to investigate in vitro the optimal antifungal lock treatment details against a Candida albicans biofilm.

Methods: An in vitro model of a C. albicans (ATCC 3153 or ATCC 66396) biofilm associated with 100% silicone catheters was used. The effectiveness of the antifungal treatment was assayed against biofilms aged 12 h or 5 days, after exposure to caspofungin (2 mg/L) or micafungin (5 mg/L) for 12 h. The durability of the reduction in the biofilm metabolic activity was investigated (1–3 days after echinocandin treatment). The efficacy of caspofungin and micafungin was determined by evaluating a significant decrease (P < 0.0001) in the metabolic activity of biofilm yeasts.

Results: The results showed that the tested antifungal agents used as lock solution significantly (P < 0.0001) reduced the metabolic activity of C. albicans, whatever the biofilm maturation stage (12 h or 5 days old biofilms). The reduction in the metabolic activity of biofilm yeasts was maintained, even after 48 h.

Conclusions: These data suggest that caspofungin (2 mg/L) and micafungin (5 mg/L) could represent good candidates for the reduction or control of fungal biofilms associated with silicone medical devices, as part of an antifungal lock. They were able to induce a significant and persistent reduction in the yeast metabolic activity of intermediate and mature biofilms, 12 h and 5 days old, respectively, when used as catheter lock solutions.

Keywords: echinocandins , yeasts , silicone , susceptibility


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
J. A. G. Ferreira, J. H. Carr, C. E. F. Starling, M. A. de Resende, and R. M. Donlan
Biofilm Formation and Effect of Caspofungin on Biofilm Structure of Candida Species Bloodstream Isolates
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4377 - 4384.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. L. Lazzell, A. K. Chaturvedi, C. G. Pierce, D. Prasad, P. Uppuluri, and J. L. Lopez-Ribot
Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis
J. Antimicrob. Chemother., September 1, 2009; 64(3): 567 - 570.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. P. Pai
Antifungal Combinations against Simulated Candida albicans Endocardial Vegetations
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2629 - 2631.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. J. Jacobson, K. E. Steckelberg, K. E. Piper, J. M. Steckelberg, and R. Patel
In Vitro Activity of Micafungin against Planktonic and Sessile Candida albicans Isolates
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2638 - 2639.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
C. M Bland and S. Thomas
Micafungin plus Fluconazole in an Infected Knee with Retained Hardware due to Candida albicans
Ann. Pharmacother., March 1, 2009; 43(3): 528 - 531.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.